Thermoregulation Among Individuals With First-episode Psychosis

Psychosis Clinical Trial

Official title:

Thermoregulation Among Individuals With First-episode Psychosis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04369677
• Other study ID #: 2020H0066
• Status: Withdrawn
• Start date: November 1, 2023
• Est. completion date: April 3, 2025

Study information

• Verified date: January 2024
• Source: Ohio State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The project will evaluate thermoregulatory processes among individuals with and without first-episode psychosis.

Description:

The project will evaluate thermoregulatory processes among individuals with and without first-episode psychosis.

Aim 1: Assess whether individuals with first-episode psychosis have differences in mean temperature and diurnal temperature variation as compared to individuals without psychosis.

Aim 2: Examine whether mean temperature and temperature variation during periods of rest and activity are different between individuals with first-episode psychosis versus people without psychosis.

Aim 3: Explore the association between current core body temperature and current ratings of psychotic symptomatology among individuals with first-episode psychosis.

Study participants will complete baseline assessments (e.g., symptoms, functioning, and sleep) and then complete a 24-36 hour ambulatory assessment period in which core temperature, activity, sleep, and heart rate variability will be tracked continuously and symptom severity will be assessed sporadically using a symptom rating app on their smart phone. .Then they will complete a second study visit to repeat baseline assessments.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 3, 2025
• Est. primary completion date: April 3, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Eligibility for Individuals with First-Episode Psychosis:

1. Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5 .

2. Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory.

3. No evidence of a pre-existing intellectual disability defined as a premorbid IQ >70 as estimated using the Reading subtest of the Wide Range Achievement Test-4.

Eligibility for Individuals without First-Episode Psychosis:

1. No diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5.

2. No evidence of a pre-existing intellectual disability defined as a premorbid IQ >70 as estimated using the Reading subtest of the Wide Range Achievement Test-4.

Eligibility for Individuals with and without First-Episode Psychosis:

1. Ages 18 - 35

2. No evidence of swallowing difficulties as assessed using the Swallowing Disturbance Questionnaire [SDQ]. defined as (i) a score <5 on the SDQ oral phase questions, (ii) a score <11.5 on the laryngopharygeal phase SDQ questions, and a total SDQ score < 12.5.

3. Not meeting diagnostic criteria for a substance use disorder over the past month as determined using the Structured Clinical Interview for the DSM-5 .

4. No current or past diagnosis of a medical condition known to affect thermoregulatory Functioning as assessed using the Health Conditions that Affect Thermoregulation questionnaire

5. Per recommendations from the manufacturer of the CorTemp continuous temperature sensor, we will not enroll:

1. Individuals who weigh less than 80 pounds

2. Individuals diagnosed with known or suspected obstructive diseases of the gastrointestinal tract

3. Individuals with a history of gag reflex disorders or impairments

4. Individuals with previous or scheduled gastrointestinal surgery

5. Individuals having felinization of the esophagus

6. Individuals with conditions that would result in hypomotility of the GI tract.

7. Individuals scheduled to undergo Magnetic Resonance Imaging or Nuclear Magnetic Resonance in the next month

8. Individuals with cardiac pacemaker or other implanted electric medical devices

Related Conditions & MeSH terms

• First Episode Psychosis
• Mental Disorders
• Psychosis
• Psychotic Disorders

Locations

Country	Name	City	State
United States	Harding Hospital	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Nicholas Breitborde

Country where clinical trial is conducted

United States, 

References & Publications (25)

Arnold VK, Rosenthal TL, Dupont RT, Hilliard D. Redundant clothing: a readily observable marker for schizophrenia in the psychiatric emergency room population. J Behav Ther Exp Psychiatry. 1993 Mar;24(1):45-7. doi: 10.1016/0005-7916(93)90007-j. — View Citation

Auther, A., C. Smith, and B. Cornblatt, Global Functioning: Social Scale (GF: Social). Glen Oaks, NY: Zucker-Hillside Hospital, 2006.

Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4. — View Citation

Cheshire WP Jr. Thermoregulatory disorders and illness related to heat and cold stress. Auton Neurosci. 2016 Apr;196:91-104. doi: 10.1016/j.autneu.2016.01.001. Epub 2016 Jan 6. — View Citation

Chong TW, Castle DJ. Layer upon layer: thermoregulation in schizophrenia. Schizophr Res. 2004 Aug 1;69(2-3):149-57. doi: 10.1016/s0920-9964(03)00222-6. — View Citation

Cohen JT, Manor Y. Swallowing disturbance questionnaire for detecting dysphagia. Laryngoscope. 2011 Jul;121(7):1383-7. doi: 10.1002/lary.21839. Epub 2011 Jun 10. — View Citation

First, M.B., et al., Structured Clinical Interview for DSM-5-Research Version2015, Arlington, VA: American Psychiatric Association.

Hayashida S, Oka T, Mera T, Tsuji S. Repeated social defeat stress induces chronic hyperthermia in rats. Physiol Behav. 2010 Aug 4;101(1):124-31. doi: 10.1016/j.physbeh.2010.04.027. Epub 2010 May 10. — View Citation

Hays, R.D., S. Prince-Embury, and H.Y. Chen, RAND-36 Health Status Inventory1998, San Antonio, TX: The Psychological Corporation.

Heh CW, Herrera J, DeMet E, Potkin S, Costa J, Sramek J, Hazlett E, Buchsbaum MS. Neuroleptic-induced hypothermia associated with amelioration of psychosis in schizophrenia. Neuropsychopharmacology. 1988 May;1(2):149-56. doi: 10.1016/0893-133x(88)90006-1. — View Citation

Horvath G, Kekesi G, Petrovszki Z, Benedek G. Abnormal Motor Activity and Thermoregulation in a Schizophrenia Rat Model for Translational Science. PLoS One. 2015 Dec 2;10(12):e0143751. doi: 10.1371/journal.pone.0143751. eCollection 2015. — View Citation

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261. — View Citation

Keeney AJ, Hogg S, Marsden CA. Alterations in core body temperature, locomotor activity, and corticosterone following acute and repeated social defeat of male NMRI mice. Physiol Behav. 2001 Sep 1-15;74(1-2):177-84. doi: 10.1016/s0031-9384(01)00541-8. — View Citation

Lkhagvasuren B, Nakamura Y, Oka T, Sudo N, Nakamura K. Social defeat stress induces hyperthermia through activation of thermoregulatory sympathetic premotor neurons in the medullary raphe region. Eur J Neurosci. 2011 Nov;34(9):1442-52. doi: 10.1111/j.1460-9568.2011.07863.x. Epub 2011 Oct 6. — View Citation

Lu BY, Cullen CE, Eide CE, Williams CC, Apfeldorf WJ. Antidepressant-induced sweating alleviated by aripiprazole. J Clin Psychopharmacol. 2008 Dec;28(6):710-1. doi: 10.1097/JCP.0b013e31818d6b67. No abstract available. — View Citation

Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease. Mov Disord. 2007 Oct 15;22(13):1917-21. doi: 10.1002/mds.21625. — View Citation

Mazerolle SM, Ganio MS, Casa DJ, Vingren J, Klau J. Is oral temperature an accurate measurement of deep body temperature? A systematic review. J Athl Train. 2011 Sep-Oct;46(5):566-73. doi: 10.4085/1062-6050-46.5.566. — View Citation

Niendam, T., et al., Global Functioning: Role Scale (GF: Role). Los Angeles, CA: University of California, Los Angeles, 2006.

Palmier-Claus JE, Ainsworth J, Machin M, Barrowclough C, Dunn G, Barkus E, Rogers A, Wykes T, Kapur S, Buchan I, Salter E, Lewis SW. The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry. 2012 Oct 17;12:172. doi: 10.1186/1471-244X-12-172. — View Citation

Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res. 2000 Jul 7;44(1):1-10. doi: 10.1016/s0920-9964(99)00161-9. — View Citation

Radonjic NV, Petronijevic ND, Vuckovic SM, Prostran MS, Nesic ZI, Todorovic VR, Paunovic VR. Baseline temperature in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Physiol Behav. 2008 Feb 27;93(3):437-43. doi: 10.1016/j.physbeh.2007.10.003. Epub 2007 Oct 10. — View Citation

Rubinstein G. Schizophrenia, infection and temperature. An animal model for investigating their interrelationships. Schizophr Res. 1993 Aug;10(2):95-102. doi: 10.1016/0920-9964(93)90043-i. — View Citation

Shiloh R, Schapir L, Bar-Ziv D, Stryjer R, Konas S, Louis R, Hermesh H, Munitz H, Weizman A, Valevski A. Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients. Eur Neuropsychopharmacol. 2009 Sep;19(9):654-8. doi: 10.1016/j.euroneuro.2009.04.010. Epub 2009 Jun 2. — View Citation

Vybiral S, Jansky L. The role of dopaminergic pathways in thermoregulation in the rabbit. Neuropharmacology. 1989 Jan;28(1):15-20. doi: 10.1016/0028-3908(89)90061-0. — View Citation

Wilkinson, G.S. and G.J. Robertson, Wide Range Achievement Test (WRAT4)2006, Lutz, FL: PAR, Inc

* Note: There are 25 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differences in mean temperature and diurnal temperature variation	Differences in mean temperature and diurnal temperature variation in individuals with first-episode psychosis as compared to individuals without psychosis.	24 hour intervals
Primary	Differences in mean temperature and temperature variation during periods of rest and activity	Differences in mean temperature and temperature variation during periods of rest and activity between individuals with first-episode psychosis versus people without psychosis.	24 hour intervals
Primary	Association of core body temperature and ratings of psychotic symptomatology in FEP	Association between core body temperature and ratings of psychotic symptomatology among individuals with first-episode psychosis.	24 hour intervals